Clinical Characteristics and Prognosis of Gastric Cancer Patients with
BRCA1
BRCA2
DNA-damaging agents
PARP inhibitors
gastric cancer
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
08
2020
accepted:
09
10
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
epublish
Résumé
The prognosis of gastric cancer (GC) is poor with a median overall survival (OS) of less than 12 months in advanced-stage disease. The search for distinct genetic subgroups of GC patients and predictive biomarkers is ongoing. While A retrospective multi-center data analysis of GC patients with gBRCAm was conducted, detailing the clinical characteristics and disease course in this unique subset of patients. Ten GC patients with gBRCAm were identified, six of them with metastatic disease. The median OS of all ten GC patients was 47.5 (13-192) months. Median OS for patients diagnosed with operable disease was 55.5 (13-192) months and of the patients with metastatic disease (calculated from metastatic disease diagnosis) 32 (15-52) months with an exceptional 1-, 2- and 3-year survival rate of 100%, 83.3% and 50%, respectively. These preliminary data suggest that gBRCAm in GC patients are associated with a favorable prognosis. Furthermore, gBRCAm might be a predictive biomarker to DNA-damaging agents response in GC patients, similarly to its established role in other malignancies. Further research is needed to confirm our findings.
Sections du résumé
BACKGROUND
BACKGROUND
The prognosis of gastric cancer (GC) is poor with a median overall survival (OS) of less than 12 months in advanced-stage disease. The search for distinct genetic subgroups of GC patients and predictive biomarkers is ongoing. While
PATIENTS AND METHODS
METHODS
A retrospective multi-center data analysis of GC patients with gBRCAm was conducted, detailing the clinical characteristics and disease course in this unique subset of patients.
RESULTS
RESULTS
Ten GC patients with gBRCAm were identified, six of them with metastatic disease. The median OS of all ten GC patients was 47.5 (13-192) months. Median OS for patients diagnosed with operable disease was 55.5 (13-192) months and of the patients with metastatic disease (calculated from metastatic disease diagnosis) 32 (15-52) months with an exceptional 1-, 2- and 3-year survival rate of 100%, 83.3% and 50%, respectively.
CONCLUSION
CONCLUSIONS
These preliminary data suggest that gBRCAm in GC patients are associated with a favorable prognosis. Furthermore, gBRCAm might be a predictive biomarker to DNA-damaging agents response in GC patients, similarly to its established role in other malignancies. Further research is needed to confirm our findings.
Identifiants
pubmed: 33235458
doi: 10.2147/OTT.S276814
pii: 276814
pmc: PMC7677647
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11637-11644Informations de copyright
© 2020 Halpern et al.
Déclaration de conflit d'intérêts
Dr Talia Golan reports grants and personal fees from AstraZeneca during the conduct of the study. The authors report no other potential conflicts of interest for this work.
Références
Oncologist. 2011;16(10):1397-402
pubmed: 21934105
Cancer. 2018 Apr 1;124(7):1374-1382
pubmed: 29338080
Br J Cancer. 2001 Feb;84(4):478-81
pubmed: 11207041
J Clin Oncol. 2002 Mar 15;20(6):1480-90
pubmed: 11896095
N Engl J Med. 2017 Nov 2;377(18):1792-3
pubmed: 29091556
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12
pubmed: 25583476
J Cell Mol Med. 2020 Jul 20;:
pubmed: 32686903
Nat Commun. 2015 Oct 29;6:8683
pubmed: 26511885
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Br J Cancer. 2014 Sep 9;111(6):1132-8
pubmed: 25072261
Lancet Oncol. 2017 Dec;18(12):1637-1651
pubmed: 29103871
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
JCO Precis Oncol. 2018;2:
pubmed: 31608315
J Clin Oncol. 2018 Oct 1;36(28):2836-2844
pubmed: 30110194
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Fam Cancer. 2012 Jun;11(2):235-42
pubmed: 22187320
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Breast Cancer Res Treat. 2018 Feb;167(3):697-702
pubmed: 29086229
Breast Cancer Res Treat. 2018 Nov;172(1):151-157
pubmed: 30014164
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
pubmed: 10433620
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117